Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Benzinga · 1d ago
Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.